Skip to main content

Ingrid Mayer Archives

VICC’s Mayer departing to take new role with AstraZeneca

Oct. 28, 2021—Ingrid Mayer, MD, MSCI, is departing Vanderbilt University Medical Center for a new role as an executive with AstraZeneca.

Read more


Vanderbilt researchers present new data on clinical trials at ASCO 2021

May. 26, 2021—Vanderbilt-Ingram Cancer Center researchers will present data on clinical trials involving targeted therapies, immunotherapies and drug combination synergies at the 2021 American Society of Clinical Oncology Annual Meeting, June 4-8. The meeting is a virtual event this year.

Read more


Health workers sought for hydroxychloroquine study

Apr. 23, 2020—Health care workers at Vanderbilt University Medical Center at high risk of exposure to COVID-19 can participate in a randomized, controlled clinical trial testing the effectiveness of the drug hydroxychloroquine (HCQ) in preventing infection.

Read more


Grant strengthens breast cancer research efforts

Aug. 22, 2019—Breast cancer researchers at Vanderbilt-Ingram Cancer Center have secured a fourth round of continuous Specialized Program of Research Excellence funding.

Read more


Clinical study tests drug that may prevent cancer metastasis

Jul. 8, 2019—A clinical study of a drug that may block cancer metastasis is currently enrolling patients at the Vanderbilt-Ingram Cancer Center.

Read more


VUMC drug repurposing initiative gaining momentum

Apr. 19, 2018—Drug repurposing involves establishing an additional approved indication for a drug already at market.

Read more


VICC breast cancer leaders named Komen Scholars

Apr. 12, 2018—Ingrid Mayer, MD, MSCI, Ingram Professor of Cancer Research and leader of the Breast Cancer Research Program at Vanderbilt-Ingram Cancer Center (VICC), has been named a Komen Scholar for her leadership in breast cancer research.

Read more


Study to test combination therapy for breast cancer

Oct. 26, 2017—Vanderbilt-Ingram Cancer Center (VICC) has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.

Read more


Breast cancer program lands new research grants

Mar. 23, 2017—Several investigators in Vanderbilt-Ingram Cancer Center’s (VICC) Breast Cancer Program have received grant awards to support translational research that may improve disease outcomes for patients.

Read more


Precision medicine already changing cancer treatment strategies

May. 26, 2016—The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more